Amicus Therapeutics Inc [FOLD] stock prices are up 6.57% to $10.55 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FOLD shares have gain 6.57% over the last week, with a monthly amount glided 12.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on September 18, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, Morgan Stanley upgraded its rating to Overweight on July 17, 2025, and kept the price target unchanged to $108. On December 13, 2024, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $12 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $18 on September 06, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $18 as its price target on May 30, 2024. Guggenheim upgraded its rating to Buy for this stock on May 14, 2024, but kept the price target unchanged to $13. In a note dated December 19, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $15 to $20.
The stock price of Amicus Therapeutics Inc [FOLD] has been fluctuating between $5.51 and $10.57 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $10.55 at the most recent close of the market. An investor can expect a potential return of 32.7% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
The Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 598.70M for trailing twelve months, representing a surge of 19.46%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.1 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.89 points at the first support level, and at 9.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.11, and for the 2nd resistance point, it is at 11.66.
Ratios To Look Out For
It’s worth pointing out that Amicus Therapeutics Inc [NASDAQ:FOLD]’s Current Ratio is 2.99. In addition, the Quick Ratio stands at 2.09 and the Cash Ratio stands at 0.96. Considering the valuation of this stock, the price to sales ratio is 5.44, the price to book ratio is 14.12.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Dec 01 ’25 when 14587.0 shares were sold. Director, BRADLEY CAMPBELL completed a deal on Dec 01 ’25 to buy 14587.0 shares. Meanwhile, Chief Development Officer Castelli Jeff sold 76158.0 shares on Nov 24 ’25.
